Old drugs, new hope: imatinib combo tested for rare tumors

NCT ID NCT01046487

Completed Disease control Sponsor: Centre Oscar Lambret Source: ClinicalTrials.gov ↗

First seen Jun 27, 2026 · Last updated Jun 27, 2026

Summary

This early-phase trial tested two cancer drugs—imatinib mesylate and cyclophosphamide—given daily by mouth to 26 people with rare, advanced tumors that had no standard treatment. The main goal was to find the safest dose of imatinib when combined with a fixed dose of cyclophosphamide. Researchers also looked for any signs that the drugs could shrink or control the tumors.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance: Imatinib mesylate and cyclophosphamide
What this could lead to: If successful, this could point toward a new treatment option for people with rare, advanced cancers that have no standard therapy.
What could go wrong: This is an early Phase 1 trial with only 26 participants, focused on safety and dosing. It is too small to prove effectiveness, and the combination may cause side effects or fail to shrink tumors.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for CANCER are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

adenoid cystic carcinoma cancer chordoma dermatofibrosarcoma protuberans desmoid tumor gastrointestinal stromal tumor neoplasm Uveal Melanoma

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

CANCER

Contacts and locations

Locations

Centre Léon Bérard

Lyon, 69008, France
Centre Oscar Lambret

Lille, 59020, France
Institut Bergonié

Bordeaux, 33076, France

More trials for these conditions

Other studies related to the condition(s) this trial covers.